<table>
<thead>
<tr>
<th>Reference</th>
<th>057</th>
</tr>
</thead>
</table>
| **Intervention:** | Botulinum toxin type A injection for the treatment of refractory diabetic gastroparesis in adults  
(Botulinum toxin is a protein complex derived from the bacterium *Clostridium botulinum*) |
| Date of Decision | November 2016 |
| Date of Issue | December 2016 (time limited approval for 1 year to December 2017) |
| **Recommendation:** | RED – suitable for prescribing and supply by hospital only |

**Further Information**

- Botulinum toxin type A injection is accepted for use in SEL as a 3rd line option for the treatment of refractory diabetic gastroparesis in adults if the following criteria are met:
  - First line management options fail, including: optimisation of glycaemic control, fluid and electrolyte replacement, nutritional support, and review of medicines that can cause symptoms of delayed gastric emptying AND
  - Patients are refractory to or not suitable (due to a contraindication or intolerance) for 2nd line treatment with prokinetics (metoclopramide, domperidone and erythromycin) in line with the NICE treatment pathway for gastroparesis in type 1 diabetes and type 2 diabetes. All of these must have been tried/considered before botulinum toxin type A injection.
  - Botulinum toxin type A is administered via intrapyloric injection in this indication. A dose of 50 units per quadrant of the pylorus will be delivered, up to a total dose of 200 units.
  - Treatment effectiveness will be measured using the gastroparesis cardinal symptom index questionnaire and individual patient clinical status, including HbA1c.
  - Where the first injection is not considered effective, a further injection can be considered. If there is no response to the second injection, no further botulinum toxin type A injections will be administered to the patient.
  - Where treatment is considered effective, treatment with botulinum toxin type A injection may be repeated at a minimum of 4 monthly intervals.
  - Botulinum toxin type A injection is a tariff excluded, CCG commissioned medicine for this indication and will be classified as a B* medicine locally.
  - A B* notification form will need to be completed and submitted to commissioners for each patient treated with botulinum toxin for diabetic gastroparesis in order for the cost of the medicine to be reimbursed to the Trust.
  - Only the most cost effective brand of botulinum toxin type A injection will be commissioned for use, taking into consideration any negotiated prices.
  - This approval is time limited to 1 year. Trusts will collate and report data back to the Committee in 12 months (December 2017; to be coordinated across SEL by the Trust submitting the formulary application) outlining:
    - The total numbers of patients treated with botulinum toxin type A for diabetic gastroparesis
    - Whether use is in line with this recommendation
    - Patient related outcomes, including (i) Response to treatment [to include diabetic control] (ii) adverse effects (iii) the number of repeat injections needed
    - Impact on activity, including: (i) number of hospital admissions related to diabetic gastroparesis before and after treatment (ii) the need for surgery and (iii) follow up appointments.
  - The Committee will review the formulary status following presentation of this report.
  - **Note:** At the time of writing there are no brands of botulinum toxin type A injection licensed for the treatment of diabetic gastroparesis and administration via the intrapyloric route is not licensed. Patients should be made aware of this before treatment is started.
<table>
<thead>
<tr>
<th>Shared Care/Transfer of care required:</th>
<th>N/A</th>
</tr>
</thead>
</table>
| **Cost Impact for agreed patient group** | • If it is estimated there may be up to 10 people per Trust per year eligible for treatment with botulinum toxin, this equates to 30 people across SEL per year.  
• Assuming treatment is with the most cost effective brand (currently Xeomin®), the cost of treatment with 200 units every 4 months per patient per year (3 injections/patient/year/) would be £576 (including VAT).  
• This would result in a total cost across SEL of approximately £17,000 per year.  
• This does not include activity related costs from the appointments needed to administer the injections. However, there is a possibility that some of the overall spend could be offset by a reduction in admissions and a reduced need for surgery. |
| **Usage Monitoring & Impact Assessment** | Acute Trusts:  
• Collate data at a SEL level as outlined in “Further Information” section and present report to APC in January 2018. |
| **CCGs:** | • Monitor monthly tariff excluded high cost drugs invoicing submitted by Trusts to the South East CSU to ensure billing of most cost effective product. |
| **Evidence reviewed** | References (from evidence review)  
1. Type 1 diabetes in adults – full guideline, NG17, National Institute for Health and Care Excellence August 2015.  
5. Summary of Product Characteristics: Botox 100 units. Available online here <accessed on 05/02/2016>  

**NOTES:**  
a) Area Prescribing Committee recommendations and minutes are available publicly on the APC website.  
b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.  
c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS.